Scribe Therapeutics To Present Data In American Heart Association’s Scientific Sessions On Its Three Clinical Programs
Benzinga Newsdesk 17 hours ago
News
Scribe Therapeutics Inc. ("Scribe Therapeutics" or "the Company") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy
Scribe Therapeutics Inc. ("Scribe Therapeutics" or "the Company") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced its participation in the American Heart Association’s Scientific Sessions taking place in Chicago, IL, from November 6-9, 2026.